Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 18/20 | 0.53 |
| ▸ | AURKA | O14965 | 15/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078617 | 0.90 | AURKB (0.64) | AURKBAURKASRCGSK3B | |
| SCHEMBL648099 | 0.88 | AURKA (0.58) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL1816236 | 0.88 | AURKB (0.55) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL62264 | 0.86 | AURKA (0.55) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL1056600 | 0.86 | AURKB (0.48) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL1299976 | 0.86 | AURKB (0.51) | AURKBAURKASRCGSK3B | |
| SCHEMBL3324241 | 0.86 | AURKA (0.44) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL1052566 | 0.86 | AURKB (0.46) | AURKBAURKASRCGSK3BAURKC | |
| SCHEMBL3324249 | 0.85 | MAPT (0.43) | AURKBAURKASRCGSK3B | |
| SCHEMBL2713578 | 0.81 | MEN1 (0.40) | AURKBAURKASRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2478361-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | Avila Therapeutics, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2352827-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | Avila Therapeutics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | AURKB 36/4885AURKA 47/4885SRC 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.